PIBT

• Immunotherapies
• Regenerative medicine

• Biotherapies: cell & tissue therapy / cell engineering
• Bioprocess development and associated quality controls.
• Transfer to GMP or other standard if necessary.
• Prototype testing: performance tests, comparisons, etc.
• Scientific consultancy (analysis of processes and technologies, implementation of development plans)
• Other: co-development, breakthrough technology innovation, etc.

• Biostat RM 20/50, from Sartorius Stedim
• iCellis Nano, from Cytiva (formerly Pall)
• DasBOX mini-bioreactor system, by Eppendorf
• Sefia, by Cytiva
• Sartoflow Smart, by Sartorius Stedim
• CliniMACS Prodigy, by Miltenyi Biotec
• MACSQuant 16, by Miltenyi Biotec

• UMR RIGHT
• FEMTO-ST

Objectives: 

• Maximising the results of research by setting up a team specialising in technology transfer and innovation
• Support the maturation of research projects that have demonstrated their effectiveness and accelerate their transfer to clinical-grade production for drug development.
• Help players in the French biomanufacturing sector to overcome the challenges they face, such as the need for breakthrough technologies, industrialisation, improving yields and reducing development and production costs.
• Combine the development of technologies and biotherapies.

Missions:

The EFS Bourgogne Franche-Comté (BFC) Biotherapies Innovation Centre (PIBT) has been awarded the “Biotherapies – Bioproduction Integrator” label in May 2023. Located in an ecosystem conducive to Biomanufacturing, the PIBT supports your projects to develop biomedicines derived from immune cells (LT, LB, NK, CAR-cells, CSM, among other examples) or to innovate production processes, drawing on its scientific, technical and regulatory skills, as well as its project management skills.

The PIBT takes part in collaborative projects or provides services for third parties, depending on the needs of the players involved.

• ISO9001
• Development in view of the GMP standard

Academics

• • ERDF BioIMP project (Bioprocesses Improvement): a project structured by the PIBT and its local partners with expertise in micro- and biotechnologies. This project, supported by the Bourgogne Franche-Comté Region and financed by European Regional Development Funds, will enable the PIBT to take charge of the maturation of high-potential technologies developed by players in the sector.
  • RHU AUGMENTREG (AP-HP, ANR): project financed by the ANR and concerning the development of an innovative biomedicine aimed at improving solid organ transplants. PIBT’s role in this project will be to optimise the production process for this genetically modified innovative therapy drug so that it complies with pharmaceutical requirements and can be produced for a phase I clinical trial.

Industrials

• Industrial project A: support for a start-up developing a therapy based on genetically modified stem cells (MSC). In this context, the PIBT is responsible for setting up analytical methods and developing the production process.
• Industrial project B: taking charge of the development of the CAR-T production process and associated quality controls, and transferring the project to the EFS pharmaceutical establishment with a view to clinical grade production at the end of 2024.
• Industrial project C: taking charge of the scale-up of NK cell production by producing development batches and pilot batches.